Human recombinant interferon alpha-2a (r IFN alpha-2a) therapy suppresses hepatic triglyceride lipase, leading to severe hypertriglyceridemia in a diabetic patient.
Yamagishi
S
S
Abe
T
T
Sawada
T
T
D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006521:Hepatitis, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008049:Lipase / Q000187:drug effects; D008099:Liver / Q000201:enzymology; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D008049:Lipase